Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies

In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice. Episode Highlights: • Understanding the current standard of care for AML, including diagnosis and risk stratification. • The importance of molecular profiling and how it influences treatment decisions. • A detailed discussion on induction chemotherapy options, including the classic 7+3 regimen and CPX351 for therapy-related AML. • Insights into the use of hypomethylating agents combined with venetoclax for patients unfit for intensive chemotherapy. • The role of targeted therapies in both upfront treatment and relapsed/refractory settings. • Key considerations for managing side effects, including cytopenias and infections. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ YouTube: https://youtu.be/gbgRbrjHxmQ Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients.  Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!